Iyer RV, et al. - In this prospective study, researchers determined the safety/efficacy and potential biomarkers for bevacizumab in combination with gemcitabine-capecitabine in advanced biliary tract cancers (BTCs). They administered 1000 mg/m² of gemcitabine (on days 1, 8), 650 mg/m² of capecitabine (on days 1 to 14), and 15 mg/kg of bevacizumab (on day 1) in 21-day cycles to inoperable stage III/IV BTC patients. At baseline and before cycle 2 and 3, they evaluated circulating tumor cells and quality of life. They found that relative to historical controls, no improved outcome was achieved with the addition of bevacizumab to gemcitabine/capecitabine in the treatment of an unselected group of patients with advanced BTC.